Ophidion is an early-stage CNS biopharmaceutical company developing non-invasive therapeutics for neurodegenerative disorders. Its proprietary carrier technology is designed to deliver large molecules and oligonucleotides into the brain via intravenous administration. The company is advancing programs in Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.